

(12) DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITÉ DE COOPÉRATION
EN MATIÈRE DE BREVETS (PCT)

(19) Organisation Mondiale de la Propriété
Intellectuelle
Bureau international



26 JAN 2005

(43) Date de la publication internationale
5 février 2004 (05.02.2004)

PCT

(10) Numéro de publication internationale
WO 2004/011464 A3

(51) Classification internationale des brevets⁷ :
C07D 487/04, C07H 17/02, A61K 31/53, 31/70, A61P
25/00, 35/00, 31/00 // (C07D 487/04, 251/00, 231/00)

(21) Numéro de la demande internationale :
PCT/FR2003/002354

(22) Date de dépôt international : 25 juillet 2003 (25.07.2003)

(25) Langue de dépôt : français

(26) Langue de publication : français

(30) Données relatives à la priorité :
02/09519 26 juillet 2002 (26.07.2002) FR

(71) Déposant (*pour tous les États désignés sauf US*) :
GREENPHARMA [FR/FR]; Biopole Clermont Limagne,
F-63360 Saint Beauzire (FR).

(72) Inventeurs; et

(75) Inventeurs/Déposants (*pour US seulement*) :
BERNARD, Philippe [FR/FR]; 16, rue des Lilas,
F-18800 Fargues-en-Septaine (FR). RABOISSON, Pierre
[FR/FR]; 26, rue de la Chênaie, F-67201 Eckbolsheim
(FR). JOSEPH, Benoît [FR/FR]; Résidence les Tamaris,
Appartement 624, 36, rue des Antonins, F-69100 Villeurbanne (FR).

(74) Mandataires : MARTIN, Jean-Jacques etc.; Cabinet
Regimbeau, 20, rue de Chazelles, F-75847 Paris Cedex 17
(FR).

(81) États désignés (*national*) : AE, AG, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ,
DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) États désignés (*régional*) : brevet ARIPO (GH, GM, KE,
LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), brevet
eurasien (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), brevet
européen (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), brevet OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).



Publiée :

- avec rapport de recherche internationale
- avant l'expiration du délai prévu pour la modification des revendications, sera republiée si des modifications sont reçues

[Suite sur la page suivante]

(54) Titre: NOVEL SUBSTITUTED PYRAZOLO[1,5-a]-1,3,5-TRIAZINE DERIVATIVES AND THEIR ANALOGUES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, USE THEREOF AS MEDICINE AND METHODS FOR PREPARING SAME

(54) Titre : NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION



(57) Abstract: The invention concerns novel substituted pyrazolo[1,5-a]-1,3,5-triazine derivatives and some of their structural analogues, and their therapeutic uses, more particularly for preventing and treating pathologies involving central and/or peripheral neuronal degeneration. The invention also concerns methods for preparing same and novel synthesis intermediates. The compounds of the invention correspond more particularly to general formulae (Ia) and (Ib).

(57) Abrégé : L'invention concerne notamment de nouveaux dérivés de pyrazolo[1,5-a]-1,3,5-triazines ainsi que certains de leurs analogues structuraux et leurs applications dans le domaine thérapeutique tout particulièrement pour la prévention et le traitement de pathologies impliquant une dégénérescence des neurones centraux et/ou périphériques. Elle concerne également des procédés pour leur préparation et de nouveaux intermédiaires de synthèse. Les composés de l'invention répondent plus particulièrement aux formules générales (Ia) et (Ib).



(88) Date de publication du rapport de recherche
internationale: 26 août 2004

En ce qui concerne les codes à deux lettres et autres abréviations, se référer aux "Notes explicatives relatives aux codes et abréviations" figurant au début de chaque numéro ordinaire de la Gazette du PCT.

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D487/04 C07H17/02 A61K31/53 A61K31/70 A61P25/00 A61P35/00 A61P31/00 // (C07D487/04, 251:00, 231:00)																			
According to International Patent Classification (IPC) or to both national classification and IPC																			
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D A61K A61P C07H																			
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																			
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, CHEM ABS Data																			
C. DOCUMENTS CONSIDERED TO BE RELEVANT <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left; padding: 2px;">Category *</th> <th style="text-align: left; padding: 2px;">Citation of document, with indication, where appropriate, of the relevant passages</th> <th style="text-align: left; padding: 2px;">Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;">X</td> <td style="padding: 2px;">WO 99/38868 A (DU PONT PHARM CO) 5 August 1999 (1999-08-05) cited in the application examples 3A et 6A claims 1,7 -----</td> <td style="padding: 2px;">1,3</td> </tr> <tr> <td style="padding: 2px;">A</td> <td style="padding: 2px;">-----</td> <td style="padding: 2px;">1,12,15</td> </tr> <tr> <td style="padding: 2px;">X</td> <td style="padding: 2px;">WO 01/23388 A (NEUROGEN; PFIZER) 5 April 2001 (2001-04-05) examples 5C ET 6C -----</td> <td style="padding: 2px;">3</td> </tr> <tr> <td></td> <td></td> <td style="padding: 2px;">-/-</td> </tr> </tbody> </table>					Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	WO 99/38868 A (DU PONT PHARM CO) 5 August 1999 (1999-08-05) cited in the application examples 3A et 6A claims 1,7 -----	1,3	A	-----	1,12,15	X	WO 01/23388 A (NEUROGEN; PFIZER) 5 April 2001 (2001-04-05) examples 5C ET 6C -----	3			-/-
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																	
X	WO 99/38868 A (DU PONT PHARM CO) 5 August 1999 (1999-08-05) cited in the application examples 3A et 6A claims 1,7 -----	1,3																	
A	-----	1,12,15																	
X	WO 01/23388 A (NEUROGEN; PFIZER) 5 April 2001 (2001-04-05) examples 5C ET 6C -----	3																	
		-/-																	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.																	
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed																			
Date of the actual completion of the international search 8 March 2004		Date of mailing of the international search report 16.06.2004																	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel: (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Alfaro Faus, I																	

Renseignements relatifs aux membres de familles de brevets

Demande internationale No PCT/FR 03/02354

Document brevet cité au rapport de recherche	Date de publication	Membre(s) de la famille de brevet(s)	Date de publication
WO 9938868	A 05-08-1999	US 6191131 B1 US 6313124 B1 US 6060478 A AT 264860 T AU 748818 B2 AU 2478799 A BR 9908206 A CA 2314613 A1 CN 1137123 C DE 69916578 D1 EP 1344779 A1 EP 1049699 A1 JP 2002501922 T NZ 505079 A NZ 524842 A PL 342183 A1 TW 520372 B WO 9938868 A1 US 6358950 B1 US 2003008885 A1	20-02-2001 06-11-2001 09-05-2000 15-05-2004 13-06-2002 16-08-1999 05-12-2000 05-08-1999 04-02-2004 27-05-2004 17-09-2003 08-11-2000 22-01-2002 29-08-2003 31-10-2003 21-05-2001 11-02-2003 05-08-1999 19-03-2002 09-01-2003
WO 0123388	A 05-04-2001	AU 7737988 A BG 106507 A CA 2379633 A1 CN 1377355 T CZ 20021089 A3 EP 1218381 A2 HU 0203131 A2 JP 2003510326 T NO 20021357 A PL 354982 A1 WO 0123388 A2 US 6476038 B1 ZA 200202517 A	30-04-2001 29-12-2002 05-04-2001 30-10-2002 13-11-2002 03-07-2002 28-01-2003 18-03-2003 23-05-2002 22-03-2004 05-04-2001 05-11-2002 28-03-2003
WO 0250079	A 27-06-2002	FR 2818278 A1 AU 2509602 A CA 2432417 A1 EP 1345941 A1 WO 0250079 A1 US 2004048849 A1	21-06-2002 01-07-2002 27-06-2002 24-09-2003 27-06-2002 11-03-2004
FR 2230366	A 20-12-1974	CH 581137 A5 AU 6925974 A DD 113907 A5 DE 2424334 A1 FI 146174 A FR 2230366 A1 JP 50019769 A NL 7406641 A BE 815405 A1 ES 426482 A1 ZA 7403316 A	29-10-1976 27-11-1975 05-07-1975 19-12-1974 23-11-1974 20-12-1974 01-03-1975 26-11-1974 22-11-1974 01-09-1976 28-01-1976
WO 02072202	A 19-09-2002	CA 2440553 A1 EE 200300435 A EP 1368094 A1 HR 20030822 A2	19-09-2002 15-12-2003 16-12-2003 30-04-2004

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see supplementary sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

3 & 4 (in part), 12-18 (in part)

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.